Observational study on mild and moderate asthma in Italy
Official title: Mild/Moderate Asthma Network of Italy Observatory
Run by Societa Italiana di Pneumologia · NCT04796844 · Data updated 2026-11-12
This study is collecting information from adults with mild and moderate asthma in Italy to see how their condition changes over time and what treatments they are using.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Societa Italiana di Pneumologia Academic / other |
| Locations | 1 site (Genova) |
| Status | Recruiting |
| Started | May 1, 2021 |
| Main results expected | May 1, 2021 |
| Study ends | November 2032 |
| Registry record updated | November 28, 2023 |
| Trial ID | NCT04796844 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults diagnosed with mild or moderate asthma who are attending respiratory or allergy clinics.
✕Probably not a fit
Patients with severe asthma or other significant pulmonary or immunological disorders may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to collect data from a large cohort of adults with mild and moderate asthma in real-world settings to observe the epidemiological evolution of the disease. Participants will be enrolled based on their asthma diagnosis according to the GINA guidelines and will attend scheduled visits at respiratory or allergy clinics. The study will follow patients for 6 to 12 months, collecting information on their condition and the therapeutic interventions they receive. Written consent will be obtained from participants, and informative materials will be provided to them and their general practitioners.
Why it matters
Potential benefit: If successful, this study could enhance understanding of asthma management and improve treatment strategies for patients with mild and moderate asthma.
How similar studies have gone: Other observational studies have shown success in understanding asthma management, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients * Asthma diagnosis according GINA 2020 algorithm (Annex 1) * Patients enrolled in other previous or ongoing observational studies Exclusion Criteria: * Severe asthma patients according International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. \[Chung KF et al. European Respiratory Journal Feb 2014, 43 (2) 343-373; DOI: 10.1183/09031936.00202013 (Annex 2)\] * Subjects are excluded from this cohort if they exhibit interstitial lung diseases, pulmonary neoplasms, current lung infections, immunological disorders leading to the use of immunosuppressants or continuous treatment with oral steroids.
Where it's running
-
IRCCS Ospedale Policlinico San Martino
Genova, Italy Recruiting
Study contacts
- Principal investigator: Fulvio Braido — IRCCS Ospedale Policlinico San Martino, Department of Internal Medicine (DiMI), University of Genoa
- Study coordinator: Fulvio Braido
- Email: fulvio.braido@unige.it
- Phone: + 393386036913
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing two types of inhalers for mild asthma treatment
This study is testing two different types of inhalers to see which one helps people with mild asthma breathe better.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.